Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
Balance Sheet
Inspect the capital base behind the business.
Assets
$117.18M
FY 2025 · Annual
+51.2% YoYLiabilities
$10.55M
FY 2025 · Annual
-92.0% YoYEquity
$106.63M
FY 2025 · Annual
Balance Sheet
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $62.4M |
| Short-term Investments | $28.8M |
| Other Current | $2.4M |
| Total Current Assets | $93.6M |
| PP&E (Net) | $269.0K |
| Other Non-current | $4.7M |
| Total Non-current Assets | $5.0M |
| Total Assets | $98.6M |
Analysis
Selected assets total $98.6M for Latest. The largest visible component is Cash & Equivalents at $62.4M, about 63.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 8, 2026 | |
| 8-K | Current report | Oct 8, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 8, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 21, 2026 |
How much cash does AARD have?
Aardvark Therapeutics, Inc. Common Stock (AARD) reported $47.05M in cash and equivalents in fiscal 2025.
How much debt does AARD carry?
Aardvark Therapeutics, Inc. Common Stock (AARD) reported $441,000.00 of total debt, with net debt of -$46.61M.
Continue the stock analysis
Jump to another research area for this company.